SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Arthur Ashe Synthetic CCD

PatientArthur Ashe
Date of birth1980-07-10
IdentifiersMRN HR-ML013-SYN; SSN (made up) 000-13-6620
Document date2026-11-01
AuthorVivian Tolliver, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Visit

Establishing primary care for HIV after a recent diagnosis with cerebral toxoplasmosis, and for coronary artery disease after two bypass operations. Concerns: He wants to decide for himself who learns of his HIV diagnosis, and when; He wants to keep coaching and playing tennis without putting his heart at risk. [S]

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Bictegravir 50 mg, emtricitabine 200 mg, and tenofovir alafenamide 25 mg, one tablet by mouth once daily; take two hours before or six hours after antacids, calcium, iron, or magnesiumOne tablet by mouth once dailyOral route2025-09-25activeS
Pyrimethamine 25 mg oral tablet, 200 mg once, then three tablets (75 mg) by mouth daily for six weeks; course completed before intakeThree tablets by mouth daily after a 200 mg loading doseOral route2025-09-11 to 2025-10-23completedS
Sulfadiazine 500 mg oral tablet, three tablets (1500 mg) by mouth every 6 hours for six weeks; course completed before intakeThree tablets by mouth every 6 hoursOral route2025-09-11 to 2025-10-23completedS
Leucovorin 10 mg oral tablet, two tablets (20 mg) by mouth daily with pyrimethamine; course completed before intakeTwo tablets by mouth dailyOral route2025-09-11 to 2025-10-23completedS
Sulfamethoxazole 800 mg and trimethoprim 160 mg (double strength), one tablet by mouth twice dailyOne tablet by mouth twice dailyOral route2025-10-23 to 2026-10-19completedS
Aspirin 81 mg delayed-release oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2016-07-31activeS
Atorvastatin 80 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2016-08-01activeS
Ezetimibe 10 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-01-12activeS
Nitroglycerin 0.4 mg sublingual tablet, one tablet under the tongue every 5 minutes as needed for chest pain, up to 3 tablets; call 911 if pain is not better 5 minutes after the first tabletOne tablet under the tongue every 5 minutes as needed for chest pain, up to 3 dosesSublingual route2016-08-01activeS

Procedures

ProcedureDatesStatusEvidence
Coronary artery bypass grafting, four grafts, after a myocardial infarction at age 362016-12-13 to 2016-12-13completedS
Repeat coronary artery bypass grafting, two grafts, for recurrent angina; blood transfusion given2020-06-15 to 2020-06-15completedS
MRI of the head with contrast: single ring-enhancing lesion in the left frontoparietal region with surrounding edema2025-09-08 to 2025-09-08completedS
Stereotactic biopsy of the left frontoparietal lesion: necrotizing inflammation with Toxoplasma gondii organisms; no lymphoma2025-09-10 to 2025-09-10completedS
12-lead electrocardiogram: sinus rhythm 72/min, old inferior Q waves, no acute ST change2026-01-12 to 2026-01-12completedS
Advance care planning conversation, about 20 minutes2026-08-17 to 2026-08-17completedS

Immunizations

DateVaccineStatusEvidence
2021-05-03Tdap vaccinecompletedS
2025-09-18Influenza vaccine, 2025-2026 season, given in the hospitalcompletedS
2026-01-12Pneumococcal conjugate vaccine PCV20completedS
2026-01-12Hepatitis B vaccine (HepB-CpG), dose 1 of 2completedS
2026-01-12Meningococcal conjugate vaccine MenACWY, dose 1 of 2completedS
2026-02-09Hepatitis B vaccine (HepB-CpG), dose 2 of 2completedS
2026-04-13Meningococcal conjugate vaccine MenACWY, dose 2 of 2completedS
2026-04-13Recombinant zoster vaccine, dose 1 of 2completedS
2026-08-17Recombinant zoster vaccine, dose 2 of 2completedS
2026-10-19Influenza vaccine, 2026-2027 seasoncompletedS
2026-10-19COVID-19 vaccine, 2026-2027 formulacompletedS

Past Medical History

Historical biography with true dates. These events are not part of the synthetic care timeline.

Historical dateHistoryEvidence
July 31, 1979Heart attack at age 36 while teaching tennis to young people, followed by quadruple coronary artery bypass surgeryD (CLM-0002)
1983Second (double) bypass operation for recurrent chest pain, with a blood transfusionD (CLM-0003)
1988Right-arm weakness from a left-sided brain mass, removed and found to be toxoplasmosis; HIV and AIDS diagnosed, believed to have been acquired from the transfusion during the 1983 operationD (CLM-0004, CLM-0005)

Family History

RelativeConditionAge at deathEvidence
motherDied at 27 of complications from surgery; atherosclerotic heart disease at an early age reportedD (CLM-0007)
fatherHeart attacks at 55 and 59; atherosclerotic heart disease at an early age reportedD (CLM-0007)

Health Concerns

ConcernStatusEvidence
He wants to decide for himself who learns of his HIV diagnosis, and whenactiveS
He wants to keep coaching and playing tennis without putting his heart at riskactiveS

Assessment

Most recent measures: HIV 1 RNA [#/volume] (viral load) in Serum or Plasma by NAA with probe detection 0 on 2026-10-19; CD3+CD4+ (T4 helper) cells [#/volume] in Blood 318 on 2026-10-19; Leukocytes [#/volume] in Blood by Automated count 5 on 2026-10-19; Hemoglobin [Mass/volume] in Blood 14.1 on 2026-10-19; Platelets [#/volume] in Blood by Automated count 236 on 2026-10-19; Sodium [Moles/volume] in Serum or Plasma 140 on 2026-10-19; Potassium [Moles/volume] in Serum or Plasma 4.5 on 2026-10-19; Creatinine [Mass/volume] in Serum or Plasma 1.12 on 2026-10-19; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 82 on 2026-10-19; Glucose [Mass/volume] in Serum or Plasma 91 on 2026-10-19; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 27 on 2026-04-13; Cholesterol [Mass/volume] in Serum or Plasma 118 on 2026-04-13; Cholesterol in HDL [Mass/volume] in Serum or Plasma 41 on 2026-04-13; Triglyceride [Mass/volume] in Serum or Plasma 125 on 2026-04-13; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 52 on 2026-04-13; Hemoglobin A1c/Hemoglobin.total in Blood 5.4 on 2026-01-12; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 2 on 2026-07-13; Total score [AUDIT-C] 1 on 2026-08-17; Lipoprotein a [Mass/volume] in Serum or Plasma 24 on 2026-04-13; Hepatitis B virus surface Ab [Units/volume] in Serum 86 on 2026-04-13; Albumin/Creatinine [Mass Ratio] in Urine 12 on 2026-07-13; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 2026-08-17 [S]

Strengths and supports: Supports: married, with a young child, and close friends; has told only a few people about his HIV diagnosis [S]

Problems

ProblemClinical statusVerificationCodeProvenance
HIV infection, diagnosed about four months before intake with a CD4 count of 58 cells/uL and cerebral toxoplasmosis (an AIDS-defining illness); on antiretroviral therapy since; synthetic modern episode linked to the documented transfusion-acquired infectionactiveconfirmed B20S — Synthetic modern coding of the documented HIV infection and AIDS diagnosis; B20 stays the code after an AIDS-defining illness, however well the infection is controlled.
Cerebral toxoplasmosis, single left-sided lesion with right-hand weakness, diagnosed by stereotactic biopsy; six weeks of acute treatment completed; weakness recovered; on maintenance therapyactiveconfirmed B58.2S — Synthetic modern coding of the documented 1988 toxoplasmosis; the modern diagnosis was by biopsy rather than removal of the mass.
Coronary artery disease after two bypass operations (quadruple, then double), no angina; synthetic modern episode linked to the documented 1979 and 1983 operationsactiveconfirmed I25.10S — Synthetic modern diagnosis; the history remains D.
Old myocardial infarction at age 36activeconfirmed I25.2S — Synthetic coded history of the documented 1979 heart attack.
Hyperlipidemia, on high-intensity statinactiveconfirmed E78.5S — Synthetic diagnosis; no cholesterol value from his lifetime is used.

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-01-12HIV 1 RNA [#/volume] (viral load) in Serum or Plasma by NAA with probe detection42{copies}/mLBelow 20 copies/mL (limit of quantification); 0 means HIV-1 RNA not detectedHighS
2026-01-12CD3+CD4+ (T4 helper) cells [#/volume] in Blood156/uL500-1500 /uLLowS
2026-01-12Leukocytes [#/volume] in Blood by Automated count4.210*3/uL4-11 10*3/uLNormalS
2026-01-12Hemoglobin [Mass/volume] in Blood13g/dL13.2-16.6 g/dLLowS
2026-01-12Platelets [#/volume] in Blood by Automated count19810*3/uL150-400 10*3/uLNormalS
2026-01-12Sodium [Moles/volume] in Serum or Plasma139mmol/L135-145 mmol/LNormalS
2026-01-12Potassium [Moles/volume] in Serum or Plasma4.9mmol/L3.5-5.1 mmol/LNormalS
2026-01-12Creatinine [Mass/volume] in Serum or Plasma1.18mg/dL0.74-1.35 mg/dLNormalS
2026-01-12Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M78mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-01-12Glucose [Mass/volume] in Serum or Plasma92mg/dL70-99 mg/dLNormalS
2026-01-12Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma30U/L7-56 U/LNormalS
2026-01-12Cholesterol [Mass/volume] in Serum or Plasma158mg/dL<=199 mg/dLNormalS
2026-01-12Cholesterol in HDL [Mass/volume] in Serum or Plasma40mg/dL>=40 mg/dLNormalS
2026-01-12Triglyceride [Mass/volume] in Serum or Plasma150mg/dL<=149 mg/dLHighS
2026-01-12Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation88mg/dL<=99 mg/dLNormalS
2026-01-12Hemoglobin A1c/Hemoglobin.total in Blood5.4%<=5.6%NormalS
2026-01-12Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]5{score}S
2026-01-12Total score [AUDIT-C]1{score}S
2026-02-09Sodium [Moles/volume] in Serum or Plasma140mmol/L135-145 mmol/LNormalS
2026-02-09Potassium [Moles/volume] in Serum or Plasma4.8mmol/L3.5-5.1 mmol/LNormalS
2026-02-09Creatinine [Mass/volume] in Serum or Plasma1.16mg/dL0.74-1.35 mg/dLNormalS
2026-02-09Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M79mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-02-09Glucose [Mass/volume] in Serum or Plasma90mg/dL70-99 mg/dLNormalS
2026-04-13HIV 1 RNA [#/volume] (viral load) in Serum or Plasma by NAA with probe detection0{copies}/mLBelow 20 copies/mL (limit of quantification); 0 means HIV-1 RNA not detectedNormalS
2026-04-13CD3+CD4+ (T4 helper) cells [#/volume] in Blood218/uL500-1500 /uLLowS
2026-04-13Leukocytes [#/volume] in Blood by Automated count4.610*3/uL4-11 10*3/uLNormalS
2026-04-13Hemoglobin [Mass/volume] in Blood13.6g/dL13.2-16.6 g/dLNormalS
2026-04-13Platelets [#/volume] in Blood by Automated count22410*3/uL150-400 10*3/uLNormalS
2026-04-13Sodium [Moles/volume] in Serum or Plasma139mmol/L135-145 mmol/LNormalS
2026-04-13Potassium [Moles/volume] in Serum or Plasma4.7mmol/L3.5-5.1 mmol/LNormalS
2026-04-13Creatinine [Mass/volume] in Serum or Plasma1.15mg/dL0.74-1.35 mg/dLNormalS
2026-04-13Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M80mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-04-13Glucose [Mass/volume] in Serum or Plasma94mg/dL70-99 mg/dLNormalS
2026-04-13Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma27U/L7-56 U/LNormalS
2026-04-13Cholesterol [Mass/volume] in Serum or Plasma118mg/dL<=199 mg/dLNormalS
2026-04-13Cholesterol in HDL [Mass/volume] in Serum or Plasma41mg/dL>=40 mg/dLNormalS
2026-04-13Triglyceride [Mass/volume] in Serum or Plasma125mg/dL<=149 mg/dLNormalS
2026-04-13Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation52mg/dL<=99 mg/dLNormalS
2026-04-13Lipoprotein a [Mass/volume] in Serum or Plasma24mg/dL<=29 mg/dLNormalS
2026-04-13Hepatitis B virus surface Ab [Units/volume] in Serum86m[IU]/mL>=10 m[IU]/mLNormalS
2026-07-13HIV 1 RNA [#/volume] (viral load) in Serum or Plasma by NAA with probe detection0{copies}/mLBelow 20 copies/mL (limit of quantification); 0 means HIV-1 RNA not detectedNormalS
2026-07-13CD3+CD4+ (T4 helper) cells [#/volume] in Blood262/uL500-1500 /uLLowS
2026-07-13Sodium [Moles/volume] in Serum or Plasma140mmol/L135-145 mmol/LNormalS
2026-07-13Potassium [Moles/volume] in Serum or Plasma4.6mmol/L3.5-5.1 mmol/LNormalS
2026-07-13Creatinine [Mass/volume] in Serum or Plasma1.14mg/dL0.74-1.35 mg/dLNormalS
2026-07-13Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M80mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-07-13Glucose [Mass/volume] in Serum or Plasma93mg/dL70-99 mg/dLNormalS
2026-07-13Albumin/Creatinine [Mass Ratio] in Urine12mg/g<=29 mg/gNormalS
2026-07-13Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]2{score}S
2026-08-17Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]0{score}S
2026-08-17Total score [AUDIT-C]1{score}S
2026-10-19HIV 1 RNA [#/volume] (viral load) in Serum or Plasma by NAA with probe detection0{copies}/mLBelow 20 copies/mL (limit of quantification); 0 means HIV-1 RNA not detectedNormalS
2026-10-19CD3+CD4+ (T4 helper) cells [#/volume] in Blood318/uL500-1500 /uLLowS
2026-10-19Leukocytes [#/volume] in Blood by Automated count510*3/uL4-11 10*3/uLNormalS
2026-10-19Hemoglobin [Mass/volume] in Blood14.1g/dL13.2-16.6 g/dLNormalS
2026-10-19Platelets [#/volume] in Blood by Automated count23610*3/uL150-400 10*3/uLNormalS
2026-10-19Sodium [Moles/volume] in Serum or Plasma140mmol/L135-145 mmol/LNormalS
2026-10-19Potassium [Moles/volume] in Serum or Plasma4.5mmol/L3.5-5.1 mmol/LNormalS
2026-10-19Creatinine [Mass/volume] in Serum or Plasma1.12mg/dL0.74-1.35 mg/dLNormalS
2026-10-19Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M82mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-10-19Glucose [Mass/volume] in Serum or Plasma91mg/dL70-99 mg/dLNormalS

Social History

Vital Signs

DateMeasureValueUnitProvenance
2026-01-12Body height185cmS
2026-01-12Body weight72kgS
2026-01-12Body mass index (BMI) [Ratio]21kg/m2S
2026-01-12Systolic blood pressure118mm[Hg]S
2026-01-12Diastolic blood pressure74mm[Hg]S
2026-01-12Heart rate72/minS
2026-01-12Respiratory rate14/minS
2026-01-12Body temperature36.7CelS
2026-01-12Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-02-09Body height185cmS
2026-02-09Body weight72.6kgS
2026-02-09Body mass index (BMI) [Ratio]21.2kg/m2S
2026-02-09Systolic blood pressure116mm[Hg]S
2026-02-09Diastolic blood pressure72mm[Hg]S
2026-02-09Heart rate70/minS
2026-02-09Respiratory rate14/minS
2026-02-09Body temperature36.6CelS
2026-02-09Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-04-13Body height185cmS
2026-04-13Body weight73.8kgS
2026-04-13Body mass index (BMI) [Ratio]21.6kg/m2S
2026-04-13Systolic blood pressure120mm[Hg]S
2026-04-13Diastolic blood pressure74mm[Hg]S
2026-04-13Heart rate68/minS
2026-04-13Respiratory rate14/minS
2026-04-13Body temperature36.7CelS
2026-04-13Oxygen saturation in Arterial blood by Pulse oximetry99%S
2026-07-13Body height185cmS
2026-07-13Body weight74.6kgS
2026-07-13Body mass index (BMI) [Ratio]21.8kg/m2S
2026-07-13Systolic blood pressure118mm[Hg]S
2026-07-13Diastolic blood pressure72mm[Hg]S
2026-07-13Heart rate66/minS
2026-07-13Respiratory rate14/minS
2026-07-13Body temperature36.6CelS
2026-07-13Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-10-19Body height185cmS
2026-10-19Body weight75kgS
2026-10-19Body mass index (BMI) [Ratio]21.9kg/m2S
2026-10-19Systolic blood pressure120mm[Hg]S
2026-10-19Diastolic blood pressure74mm[Hg]S
2026-10-19Heart rate66/minS
2026-10-19Respiratory rate14/minS
2026-10-19Body temperature36.6CelS
2026-10-19Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-08-17Body height185cmS
2026-08-17Body weight74.8kgS
2026-08-17Body mass index (BMI) [Ratio]21.9kg/m2S
2026-08-17Systolic blood pressure118mm[Hg]S
2026-08-17Diastolic blood pressure72mm[Hg]S
2026-08-17Heart rate64/minS
2026-08-17Respiratory rate14/minS
2026-08-17Body temperature36.6CelS
2026-08-17Oxygen saturation in Arterial blood by Pulse oximetry98%S

Encounters

DatePurposeStatusProvenance
2026-01-12Establishing primary care for HIV after a recent diagnosis with cerebral toxoplasmosis, and for coronary artery disease after two bypass operationsfinishedS
2026-02-09Four-week check of potassium and creatinine, second hepatitis B vaccine, and infectious diseases consultationfinishedS
2026-04-13Three-month HIV and lipid reviewfinishedS
2026-07-13Six-month HIV and coronary disease review with depression screeningfinishedS
2026-10-19Nine-month HIV review: decision to stop toxoplasmosis maintenance therapyfinishedS
2026-08-17Periodic adult preventive visitfinishedS

Plan of Treatment

InterventionStatusGuidelineProvenance
Antiretroviral therapy with bictegravir, emtricitabine, and tenofovir alafenamide once daily, chosen for its high barrier to resistance and few interactions with his cardiac medicines; viral load and CD4 count every three monthscompletedGL-DHHS-ART, GL-IAS-ART-2024, GL-HIVMA-PC-2020S
Infectious diseases consultation to co-manage HIV: the regimen and its interactions, opportunistic-infection prophylaxis, the monitoring schedule, and vaccinescompletedGL-DHHS-ART, GL-DHHS-OIS
Toxoplasma maintenance therapy with trimethoprim-sulfamethoxazole double strength twice daily, which also prevents Pneumocystis pneumonia, until the CD4 count is above 200 for more than six months on suppressive therapy; blood count, potassium, and creatinine every three months while on itcompletedGL-DHHS-OIS
Secondary prevention of coronary disease after two bypass operations: aspirin, high-intensity atorvastatin with ezetimibe added for an LDL goal below 55 mg/dL, blood pressure below 130/80, a heart-healthy diet, regular exercise, and a written chest-pain plan with sublingual nitroglycerincompletedGL-CCD-2023, GL-CMID-2026S
Vaccines for adults with HIV: pneumococcal, hepatitis B with an antibody check afterwards, the two-dose meningococcal ACWY series, recombinant zoster, and seasonal influenza and COVID-19, with no live vaccines while the CD4 count is below 200completedGL-CDC-IMZ-HIV, GL-HIVMA-PC-2020S
Person-first, confidential care: he decides who learns of his diagnosis; support with disclosure if and when he chooses, peer support, and depression screening with the PHQ-9 at intake and six months and the PHQ-2 at the preventive visitcompletedGL-HIVMA-PC-2020, GL-USPSTF-DEP-2023, GL-CMID-2026S

Goals

GoalTargetStatusOutcomeProvenance
HIV-1 viral load not detected by the three-month visit2026-04-13completedViral load not detected (below 20 copies/mL) at three months, and at six and nine monthsS
CD4 count above 200 cells/uL for more than six months with an undetectable viral load, so that maintenance therapy can stop safely2026-10-19completedCD4 218 at three months, 262 at six months, and 318 at nine months; trimethoprim-sulfamethoxazole stoppedS
LDL cholesterol below 55 mg/dL by the three-month visit2026-04-13completedLDL cholesterol 52 mg/dL on atorvastatin and ezetimibeS
Hepatitis B vaccine series completed with a protective antibody level by the three-month visit2026-04-13completedHepatitis B surface antibody 86 mIU/mLS
Keep blood pressure below 130/80 mmHg2026-07-13completedBlood pressure 116 to 120 over 72 to 74 at every visitS

Functional Status

Mental Status